HIGHLIGHTS
- who: Heart failure and collaborators from the British Foundation Cardiovascular Research Centre, University of Glasgow, University Place, Glasgow , TA, UK have published the article: Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF), in the Journal: (JOURNAL)
- how: Time-to-event data were evaluated with the use of the.... The authors evaluated the effect of SGLT2 inhibition on SBP in HFrEF patients both with and without diabetes and the efficacy and safety of dapagliflozin according to baseline SBP in the Dapagliflozin . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.